Company · CIK 0001061983 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
CYTOKINETICS INC · CYTK
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 SForm 4 → | Sep 22, 6:14 pm EDT | Fady Ibraham MalikEVP Research & Development | 3,500 | $68.29 | $239,015 | 153,902 | −2.22% | 10b5-1 |
| Sep 22, 2026 MForm 4 → | Sep 22, 6:14 pm EDT | Fady Ibraham MalikEVP Research & Development | 3,500 | $7.80 | $27,300 | 157,402 | — | 10b5-1 |
| Sep 15, 2026 SForm 4 → | Sep 15, 5:23 pm EDT | Robert E LandryDirector | 1,000 | $72.13 | $72,130 | 8,184 | −10.9% | 10b5-1 |
| Sep 14, 2026 SForm 4 → | Sep 15, 5:20 pm EDT | Robert I BlumPresident & CEO, Director | 105,426 | $69.62 | $7,340,010 | 0 | −100% | 10b5-1 |
| Sep 14, 2026 GMForm 4 → | Sep 15, 5:20 pm EDT | Robert I BlumPresident & CEO, Director | 204,702 | $10.60 | $79,500 | 97,926 | — | 10b5-1 |
| Sep 11, 2026 SForm 4 → | Sep 11, 7:12 pm EDT | Robert E LandryDirector | 1,000 | $74.66 | $74,660 | 9,184 | −9.82% | 10b5-1 |
| Sep 8, 2026 SForm 4 → | Sep 8, 4:38 pm EDT | Fady Ibraham MalikEVP Research & Development | 3,500 | $75.46 | $264,110 | 153,902 | −2.22% | 10b5-1 |
| Sep 8, 2026 MForm 4 → | Sep 8, 4:38 pm EDT | Fady Ibraham MalikEVP Research & Development | 3,500 | $7.80 | $27,300 | 157,402 | — | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 1, 4:51 pm EDT | B Lynne ParshallDirector | 5,000 | $71.48 | $357,400 | 10,784 | −31.7% | 10b5-1 |
| Aug 31, 2026 SForm 4 → | Aug 31, 4:57 pm EDT | Andrew CallosEVP, Chief Commercial Officer | 10,000 | $70.24 | $702,400 | 58,555 | −14.6% | 10b5-1 |
| Aug 31, 2026 MForm 4 → | Aug 31, 4:57 pm EDT | Andrew CallosEVP, Chief Commercial Officer | 10,000 | $23.26 | $232,600 | 68,555 | — | 10b5-1 |
| Aug 31, 2026 SForm 4 → | Aug 31, 4:55 pm EDT | Robert I BlumPresident & CEO, Director | 7,500 | $70.24 | $526,800 | 377,820 | −1.95% | 10b5-1 |
| Aug 31, 2026 MForm 4 → | Aug 31, 4:55 pm EDT | Robert I BlumPresident & CEO, Director | 7,500 | $10.60 | $79,500 | 385,320 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 MForm 4 → | Sep 22, 6:14 pm EDT | Fady Ibraham MalikEVP Research & Development | 3,500 | — | — | 23,386 | — | 10b5-1 |
| Sep 14, 2026 MForm 4 → | Sep 15, 5:20 pm EDT | Robert I BlumPresident & CEO, Director | 7,500 | — | — | 156,745 | — | 10b5-1 |
| Sep 8, 2026 MForm 4 → | Sep 8, 4:38 pm EDT | Fady Ibraham MalikEVP Research & Development | 3,500 | — | — | 26,886 | — | 10b5-1 |
| Aug 31, 2026 MForm 4 → | Aug 31, 4:57 pm EDT | Andrew CallosEVP, Chief Commercial Officer | 10,000 | — | — | 0 | — | 10b5-1 |
| Aug 31, 2026 MForm 4 → | Aug 31, 4:55 pm EDT | Robert I BlumPresident & CEO, Director | 7,500 | — | — | 164,245 | — | 10b5-1 |